Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Gemcitabine/Cisplatin Plus Toripalimab Treatment: a Single Arm, Open Label, Multicenter, Phase II Clinical Study

NCT05484375 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor.

NCT NCT05484375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05484375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Gemcitabine/Cisplatin Plus Toripalimab Treatment: a Single Arm, Open Label, Multicenter, Phase II Clinical Study
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2022
Completion date
September 30, 2029
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nasopharyngeal carcinoma